H.C. Wainwright raised the firm’s price target on Relay Therapeutics (RLAY) to $25 from $19 and keeps a Buy rating on the shares. The firm says the Phase 1 zovegalisib triplet results “derisk” the planned Phase 3 trial.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RLAY:
- Relay Therapeutics price target raised to $18 from $14 at Oppenheimer
- Relay Therapeutics price target raised to $21 from $17 at Wells Fargo
- Relay Therapeutics price target raised to $22 from $13 at Goldman Sachs
- Relay Therapeutics price target raised to $19 from $17 at Citizens
- Analyst Reiterates Buy on Relay Therapeutics, Citing Promising Zovega mBC Data, Favorable Safety Profile, and Phase 3 First-Line Breast Cancer Upside